학술논문
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study
Document Type
article
Author
Stefano Partelli; John K. Ramage; Sara Massironi; Alessandro Zerbi; Hong Beom Kim; Patricia Niccoli; Francesco Panzuto; Luca Landoni; Ales Tomazic; Toni Ibrahim; Gregory Kaltsas; Emilio Bertani; Alain Sauvanet; Eva Segelov; Martyn Caplin; Jorgelina Coppa; Thomas Armstrong; Martin O. Weickert; Giovanni Butturini; Stefan Staettner; Florian Boesch; Mauro Cives; Carol Anne Moulton; Jin He; Andreas Selberherr; Orit Twito; Antonio Castaldi; Claudio Giovanni De Angelis; Sebastien Gaujoux; Hussein Almeamar; Andrea Frilling; Emanuel Vigia; Colin Wilson; Francesca Muffatti; Raj Srirajaskanthan; Pietro Invernizzi; Andrea Lania; Wooil Kwon; Jacques Ewald; Maria Rinzivillo; Chiara Nessi; Lojze M. Smid; Andrea Gardini; Marina Tsoli; Edgardo E. Picardi; Olivia Hentic; Daniel Croagh; Christos Toumpanakis; Davide Citterio; Emma Ramsey; Barbara Mosterman; Paolo Regi; Silvia Gasteiger; Roberta E. Rossi; Valeria Smiroldo; Jin-Young Jang; Massimo Falconi
Source
Frontiers in Medicine, Vol 7 (2020)
Subject
Language
English
ISSN
2296-858X
Abstract
Introduction: The optimal treatment for small, asymptomatic, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN) is still controversial. European Neuroendocrine Tumor Society (ENETS) guidelines recommend a watchful strategy for asymptomatic NF-PanNEN 18 years, the presence of asymptomatic sporadic NF-PanNEN ≤2 cm proven by a positive fine-needle aspiration (FNA) or by the presence of a measurable nodule on high-quality imaging techniques that is positive at 68Gallium DOTATOC-PET scan.Conclusion: The ASPEN study is designed to investigate if an active surveillance of asymptomatic NF-PanNEN ≤2 cm is safe as compared to surgical approach.